Adjuvant bevacizumab in colon cancer: where did we go wrong?
Mené sur 2 867 patients atteints d'un carcinome du côlon de stade III ayant fait l'objet d'une résection curative ou d'un carcinome du côlon de stade II, cet essai de phase III évalue, du point de vue de la survie sans maladie, l'efficacité et la toxicité du bevacizumab en combinaison avec une chimiothérapie à base d'oxaliplatine en traitement adjuvant
The past decade has been an exciting time for research in colorectal oncology, with basic discoveries in cancer development and progression being translated into targeted therapeutics with tangible benefits for patients. However, it has also been a time of confusion, since compelling initial results have often been followed by disappointing or even adverse effects in subsequent trials. This is especially true of the move to the adjuvant setting, where our therapeutic aim shifts from control of established metastases to the eradication of occult micrometastases...
The Lancet Oncology , commentaire en libre accès, 2011